tiprankstipranks
Biogen (IT:1BIIB)
:1BIIB
Italy Market
1BIIB
Biogen
RESEARCH TOOLSreports

Biogen (1BIIB) Stock Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

1BIIB Analyst Ratings

Moderate Buy
27Ratings
Moderate Buy
17 Buy
9 Hold
1 Sell
Based on 27 analysts giving stock ratings to
Biogen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1BIIB Stock 12 Month Forecast

Average Price Target

€200.73
▲(12.76% Upside)
Based on 27 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is €200.73 with a high forecast of €257.21 and a low forecast of €134.61. The average price target represents a 12.76% change from the last price of €178.02.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"108":"€108","183":"€183","258":"€258","145.5":"€145.5","220.5":"€220.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":257.211129,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€257.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":200.73185192375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€200.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":134.60715751,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€134.61</span>\n  </div></div>","useHTML":true}}],"tickPositions":[108,145.5,183,220.5,258],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177.44,183.5762406923077,189.7124813846154,195.84872207692308,201.98496276923078,208.12120346153847,214.25744415384617,220.39368484615386,226.52992553846155,232.66616623076925,238.80240692307694,244.93864761538464,251.07488830769233,{"y":257.211129,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177.44,179.23168091721155,181.02336183442307,182.81504275163462,184.60672366884614,186.3984045860577,188.19008550326924,189.98176642048077,191.77344733769232,193.56512825490387,195.3568091721154,197.14849008932694,198.94017100653846,{"y":200.73185192375,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177.44,174.1451659623077,170.85033192461538,167.5554978869231,164.26066384923078,160.96582981153847,157.67099577384616,154.37616173615385,151.08132769846154,147.78649366076922,144.49165962307694,141.19682558538463,137.90199154769232,{"y":134.60715751,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":109.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.15,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":152.3,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.95,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.95,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.7,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":157.75,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162.88,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.74,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.48,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.44,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€257.21Average Price Target€200.73Lowest Price Target€134.61
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on IT:1BIIB
Brian Abrahams
RBC Capital
RBC Capital
€205.77→€222.92
Buy
25.22%
Upside
Assigned
08/25/26
Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (NASDAQ: GEHC), Biogen (NASDAQ: BIIB) and BeOne Medicines (NASDAQ: ONC)
Wolfe Research Analyst forecast on IT:1BIIB
Alexandria Hammond
Wolfe Research
Wolfe Research
€257.21
Buy
44.48%
Upside
Upgraded
08/13/26
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (NASDAQ: APGE) and Biogen (NASDAQ: BIIB)
Barclays Analyst forecast on IT:1BIIB
Emily Field
Barclays
Barclays
€171.47
Hold
-3.68%
Downside
Reiterated
08/12/26
Barclays Keeps Their Hold Rating on Biogen (BIIB)
Citi Analyst forecast on IT:1BIIB
Geoff Meacham
Citi
Citi
€171.47→€184.33
Hold
3.55%
Upside
Reiterated
08/03/26
Biogen price target raised to $215 from $200 at CitiBiogen price target raised to $215 from $200 at Citi
Mizuho Securities Analyst forecast on IT:1BIIB
Salim Syed
Mizuho Securities
Mizuho Securities
€189.48→€206.63
Buy
16.07%
Upside
Reiterated
08/03/26
Mizuho Securities Keeps Their Buy Rating on Biogen (BIIB)
Stifel Nicolaus Analyst forecast on IT:1BIIB
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€183.48→€207.48
Buy
16.55%
Upside
Reiterated
08/02/26
Stifel Nicolaus Remains a Buy on Biogen (BIIB)
Wedbush Analyst forecast on IT:1BIIB
Laura Chico
Wedbush
Wedbush
€184.33
Hold
3.55%
Upside
Reiterated
07/31/26
Wedbush Keeps Their Hold Rating on Biogen (BIIB)
Truist Financial Analyst forecast on IT:1BIIB
Danielle Brill
Truist Financial
Truist Financial
€201.48
Buy
13.18%
Upside
Reiterated
07/31/26
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Xencor (NASDAQ: XNCR)
H.C. Wainwright Analyst forecast on IT:1BIIB
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€203.2→€215.2
Buy
20.89%
Upside
Reiterated
07/30/26
Biogen price target raised to $251 from $237 at H.C. WainwrightBiogen price target raised to $251 from $237 at H.C. Wainwright
Jefferies Analyst forecast on IT:1BIIB
Andrew Tsai
Jefferies
Jefferies
€218.63
Buy
22.81%
Upside
Reiterated
07/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (NASDAQ: BIIB), Teladoc (NYSE: TDOC) and Damora Therapeutics (NASDAQ: DMRA)
BMO Capital Analyst forecast on IT:1BIIB
Evan Seigerman
BMO Capital
BMO Capital
€168.04→€178.33
Hold
0.18%
Upside
Reiterated
07/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (NASDAQ: BIIB), GE Healthcare Technologies Inc (NASDAQ: GEHC) and Fortrea Holdings Inc. (NASDAQ: FTRE)
Wells Fargo Analyst forecast on IT:1BIIB
Mohit Bansal
Wells Fargo
Wells Fargo
€214.34
Buy
20.40%
Upside
Reiterated
07/30/26
Wells Fargo Reaffirms Their Buy Rating on Biogen (BIIB)
Morgan Stanley Analyst forecast on IT:1BIIB
Terence Flynn
Morgan Stanley
Morgan Stanley
€190.34→€198.05
Hold
11.25%
Upside
Reiterated
07/30/26
Analysts Conflicted on These Healthcare Names: Biogen (NASDAQ: BIIB), NeuroPace (NASDAQ: NPCE) and Gilead Sciences (NASDAQ: GILD)
Canaccord Genuity Analyst forecast on IT:1BIIB
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
€210.06→€212.63
Buy
19.44%
Upside
Reiterated
07/30/26
Biogen price target raised to $248 from $245 at CanaccordBiogen price target raised to $248 from $245 at Canaccord
TD Cowen Analyst forecast on IT:1BIIB
Phil Nadeau
TD Cowen
TD Cowen
€184.33→€192.91
Buy
8.36%
Upside
Assigned
07/30/26
Analysts' Top Healthcare Picks: Icon (ICLR), Biogen (BIIB)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on IT:1BIIB
Brian Abrahams
RBC Capital
RBC Capital
€205.77→€222.92
Buy
25.22%
Upside
Assigned
08/25/26
Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (NASDAQ: GEHC), Biogen (NASDAQ: BIIB) and BeOne Medicines (NASDAQ: ONC)
Wolfe Research Analyst forecast on IT:1BIIB
Alexandria Hammond
Wolfe Research
Wolfe Research
€257.21
Buy
44.48%
Upside
Upgraded
08/13/26
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (NASDAQ: APGE) and Biogen (NASDAQ: BIIB)
Barclays Analyst forecast on IT:1BIIB
Emily Field
Barclays
Barclays
€171.47
Hold
-3.68%
Downside
Reiterated
08/12/26
Barclays Keeps Their Hold Rating on Biogen (BIIB)
Citi Analyst forecast on IT:1BIIB
Geoff Meacham
Citi
Citi
€171.47→€184.33
Hold
3.55%
Upside
Reiterated
08/03/26
Biogen price target raised to $215 from $200 at CitiBiogen price target raised to $215 from $200 at Citi
Mizuho Securities Analyst forecast on IT:1BIIB
Salim Syed
Mizuho Securities
Mizuho Securities
€189.48→€206.63
Buy
16.07%
Upside
Reiterated
08/03/26
Mizuho Securities Keeps Their Buy Rating on Biogen (BIIB)
Stifel Nicolaus Analyst forecast on IT:1BIIB
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€183.48→€207.48
Buy
16.55%
Upside
Reiterated
08/02/26
Stifel Nicolaus Remains a Buy on Biogen (BIIB)
Wedbush Analyst forecast on IT:1BIIB
Laura Chico
Wedbush
Wedbush
€184.33
Hold
3.55%
Upside
Reiterated
07/31/26
Wedbush Keeps Their Hold Rating on Biogen (BIIB)
Truist Financial Analyst forecast on IT:1BIIB
Danielle Brill
Truist Financial
Truist Financial
€201.48
Buy
13.18%
Upside
Reiterated
07/31/26
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Xencor (NASDAQ: XNCR)
H.C. Wainwright Analyst forecast on IT:1BIIB
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€203.2→€215.2
Buy
20.89%
Upside
Reiterated
07/30/26
Biogen price target raised to $251 from $237 at H.C. WainwrightBiogen price target raised to $251 from $237 at H.C. Wainwright
Jefferies Analyst forecast on IT:1BIIB
Andrew Tsai
Jefferies
Jefferies
€218.63
Buy
22.81%
Upside
Reiterated
07/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (NASDAQ: BIIB), Teladoc (NYSE: TDOC) and Damora Therapeutics (NASDAQ: DMRA)
BMO Capital Analyst forecast on IT:1BIIB
Evan Seigerman
BMO Capital
BMO Capital
€168.04→€178.33
Hold
0.18%
Upside
Reiterated
07/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (NASDAQ: BIIB), GE Healthcare Technologies Inc (NASDAQ: GEHC) and Fortrea Holdings Inc. (NASDAQ: FTRE)
Wells Fargo Analyst forecast on IT:1BIIB
Mohit Bansal
Wells Fargo
Wells Fargo
€214.34
Buy
20.40%
Upside
Reiterated
07/30/26
Wells Fargo Reaffirms Their Buy Rating on Biogen (BIIB)
Morgan Stanley Analyst forecast on IT:1BIIB
Terence Flynn
Morgan Stanley
Morgan Stanley
€190.34→€198.05
Hold
11.25%
Upside
Reiterated
07/30/26
Analysts Conflicted on These Healthcare Names: Biogen (NASDAQ: BIIB), NeuroPace (NASDAQ: NPCE) and Gilead Sciences (NASDAQ: GILD)
Canaccord Genuity Analyst forecast on IT:1BIIB
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
€210.06→€212.63
Buy
19.44%
Upside
Reiterated
07/30/26
Biogen price target raised to $248 from $245 at CanaccordBiogen price target raised to $248 from $245 at Canaccord
TD Cowen Analyst forecast on IT:1BIIB
Phil Nadeau
TD Cowen
TD Cowen
€184.33→€192.91
Buy
8.36%
Upside
Assigned
07/30/26
Analysts' Top Healthcare Picks: Icon (ICLR), Biogen (BIIB)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biogen

3 Months
Salveen RichterGoldman Sachs
Success Rate
16/27 ratings generated profit
59%
Average Return
+1.89%
Copying Salveen Richter's trades and holding each position for 3 Months would result in 59.26% of your transactions generating a profit, with an average return of +1.89% per trade.
1 Year
Myles MinterWilliam Blair
Success Rate
16/23 ratings generated profit
70%
Average Return
+16.76%
Copying Myles Minter's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +16.76% per trade.
2 Years
Myles MinterWilliam Blair
Success Rate
15/23 ratings generated profit
65%
Average Return
+13.57%
Copying Myles Minter's trades and holding each position for 2 Years would result in 65.22% of your transactions generating a profit, with an average return of +13.57% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1BIIB Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
31
39
41
54
40
Hold
40
39
32
34
23
Sell
1
1
0
1
1
Strong Sell
0
0
0
0
0
total
72
79
73
89
64
In the current month, 1BIIB has received 40 Buy Ratings, 23 Hold Ratings, and 1 Sell Ratings. 1BIIB average Analyst price target in the past 3 months is 200.73.
Each month's total comprises the sum of three months' worth of ratings.

1BIIB Financial Forecast

1BIIB Earnings Forecast

Next quarter’s earnings estimate for 1BIIB is €1.76 with a range of €1.25 to €2.31. The previous quarter’s EPS was €3.12. 1BIIB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1BIIB has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1BIIB is €1.76 with a range of €1.25 to €2.31. The previous quarter’s EPS was €3.12. 1BIIB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1BIIB has Performed in-line its overall industry.

1BIIB Sales Forecast

Next quarter’s sales forecast for 1BIIB is €2.29B with a range of €2.17B to €2.36B. The previous quarter’s sales results were €2.27B. 1BIIB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1BIIB has Performed in-line its overall industry.
Next quarter’s sales forecast for 1BIIB is €2.29B with a range of €2.17B to €2.36B. The previous quarter’s sales results were €2.27B. 1BIIB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1BIIB has Performed in-line its overall industry.

1BIIB Stock Forecast FAQ

What is IT:1BIIB’s average 12-month price target, according to analysts?
Based on analyst ratings, Biogen’s 12-month average price target is 200.73.
    What is IT:1BIIB’s upside potential, based on the analysts’ average price target?
    Biogen has 12.76% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Biogen a Buy, Sell or Hold?
          Biogen has a consensus rating of Moderate Buy, which is based on 17 buy ratings, 9 hold ratings and 1 sell ratings.
            What is Biogen’s share price target?
            The average share price target for Biogen is 200.73. This is based on 27 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €257.21 ,and the lowest forecast is €134.61. The average share price target represents 12.76% Increase from the current price of €178.02.
              What do analysts say about Biogen?
              Biogen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 27 Wall Streets Analysts.
                How can I buy shares of Biogen?
                To buy shares of IT:1BIIB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.